Welcome to Progress in Neurology and Psychiatry’s dedicated website. Progress is for health professionals in secondary and primary care looking after patients with neurological and psychiatric diseases. If you are a health professional working in the field of neurology or psychiatry you can register with us for free access to our content.Sign up for e-alerts and print copies

Latest News

Isradipine for Parkinson’s disease

To date, no treatment has been shown to delay progression of Parkinson’s disease (PD) but there is evidence that calcium channel blockers (CCBs) are...Read more

Study assesses cancer risk with MS therapies

A data-linkage study from Sweden has assessed the risk of cancer in people with multiple sclerosis after starting treatment with fingolimod, natalizumab or...Read more

Antipsychotic for schizophrenia without metabolic effects?

Lumateperone is (like haloperidol) a butyrophenone antipsychotic. Its pharmacology is complex, with activity on multiple neurotransmitters resulting in...Read more

Worse seizure control after valproate stopped

Seizure control deteriorates in many women after discontinuing valproate, a UK analysis shows. The survey of 215 specialist valproate prescribers included...Read more

Little evidence for prophylaxis of migraine in children

There is no evidence of efficacy for long term prophylaxis of migraine in children, according to a new systematic review and network analysis. The analysis,...Read more

Evidence lacking for drug treatment of cannabis use disorder

There is an urgent need for an effective treatment strategy for cannabis use disorder because recreational use is becoming common in the general population,...Read more

Mental health in the time of CoVid-19

The charity Mind has voiced its concern about the broad scope of legislation introduced by the Government as part of its strategy to tackle the CoVid-19...Read more

Featured Articles

Knowledge and attitude towards TMS: a brief educational intervention
In December 2015 NICE recognised the use of transcranial magnetic stimulation (TMS) as a viable option in the management of treatment-resistant depression. Despite this, uptake of the technique has been slow and only a small number of machines are currently in use across the UK. Here the authors describe an educational initiative to increase clinicians’ knowledge of TMS.
Click here to view

Stopping overmedication to manage challenging behaviour in LD – STOMP
STOMP (stopping overmedication of people with a learning disability (LD), autism or both with psychotropic medicines) aims to review psychotropic medicines regularly, inform everyone about non-pharmacological therapies and, most importantly, to involve patients, support staff and their families in decisions about medications. This exploratory study by Dr Javaid and team examines whether the NICE guidelines are implemented in line with STOMP when managing patients with challenging behaviours.
Click here to view

Bruxism and psychotropic medications
Bruxism as a side-effect of psychotropic medications could result in significant consequences for oral health such as tooth structure destruction and irreversible harm to the temporomandibular joint. The review findings uncovered by these authors can assist in understanding the aetiology of bruxism, establishing an appropriate management plan, while supporting psychiatrists and dentists to detect temporomandibular dysfunctions such as bruxism.
Click here to view

Web design and marketing agency Leamington Spa